Molecular Regulation of Vascular Endothelial Growth Factor Expression in the Retinal Pigment Epithelium

Citation
Ford, Knatokie M., and Patricia A. D’Amore. 2012. Molecular regulation of vascular endothelial growth factor expression in the retinal pigment epithelium. Molecular Vision 18: 519-527.

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10304564

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Molecular regulation of vascular endothelial growth factor expression in the retinal pigment epithelium

Knatokie M. Ford,1,2,4 Patricia A. D’Amore1,2,3,4

1Schepens Eye Research Institute/Massachusetts Eye and Ear, Boston, MA; 2Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, MA; 3Department of Ophthalmology, Harvard Medical School, Boston, MA; 4Department of Pathology, Harvard Medical School, Boston, MA

Purpose: Vascular endothelial growth factor (VEGF) plays an important role in homeostasis and diseases of the retinal pigment epithelium (RPE), choriocapillaris, and, most notably, age-related macular degeneration (AMD). Although much is known about VEGF regulation in pathologies, little is known about the control of VEGF expression under normal conditions. VEGF expression has been previously shown to be regulated in coordination with cell differentiation in the muscle and kidney. We therefore tested the hypothesis that VEGF in the adult RPE would similarly be regulated in conjunction with differentiation.

Methods: A human retinal pigment epithelium cell line (ARPE-19), a line of immortalized human RPE cells, was used for all experiments. RPE cells were polarized in culture for 4 weeks on laminin-coated Transwells. Levels of VEGF mRNA and protein were determined with real-time PCR and enzyme-linked immunosorbent assay, respectively. VEGF-luciferase reporter constructs were used to identify regions of the VEGF promoter that control VEGF expression in the RPE. Microphthalmia-associated transcription factor (MITF)-Tfe transcription factors were blocked using either a pan MITF-Tfe dominant negative or specific small interfering RNA (siRNA).

Results: VEGF mRNA and protein secretion increased over time in the RPE cells cultured on Transwells, with protein secretion occurring in a polarized fashion primarily toward the basolateral side. Overexpression of a dominant negative that targets the MITF-Tfe family resulted in a 50% reduction in VEGF expression. The role of the MITF-Tfe family in VEGF regulation in the RPE was corroborated in studies with the VEGF-luciferase reporter constructs, where deletion of the distal VEGF promoter region containing putative binding sites for the MITF-Tfe family resulted in a 50% reduction in VEGF promoter activity. siRNA knockdown of the MITF-Tfe family individually, and in combination, revealed that downregulation of Tfe3 resulted in reduced VEGF expression.

Conclusions: Our results indicate that Tfe3, in conjunction with other MITF-Tfe members, regulates VEGF expression in the RPE and are consistent with the hypothesis that VEGF expression in RPE cells is regulated as part of their differentiation.

Vascular endothelial growth factor (VEGF), also called VEGF-A, is a member of the cysteine-knot superfamily of growth factors, which is characterized by the presence of eight conserved cysteine residues [1,2]. VEGF has been shown to be an important regulator of normal and pathological angiogenesis, the process by which new blood vessels arise from existing ones [3]. VEGF also plays a role in controlling vascular permeability [4]. Targeted disruption of VEGF and its receptors results in early embryonic lethality due to severe defects in vasculogenesis [5–7]. VEGF expression declines postnatally, but continues in specific cells in virtually all tissues, particularly at sites proximal to fenestrated endothelium, such as podocytes adjacent to glomerular endothelium, and retinal pigment epithelium (RPE) adjacent to the choriocapillaris [8,9].

Our laboratory has shown that the RPE is the only source of VEGF in the back of the eye [10]. RPE-derived VEGF not only functions in the development [11], maintenance, and survival of the choriocapillaris and the RPE but also contributes to their pathologies. Aberrant VEGF expression by the RPE is believed to promote the progression of the choroidal neovascularization associated with the advanced form of age-related macular degeneration (AMD). However, little is known about the molecular regulation of VEGF in the RPE. Previous studies have identified various factors and conditions that are capable of influencing VEGF expression, including hypoxia, mechanical stress, advanced glycation end products, vasopressor hormones (angiotensin II, vasopressin), cytokines (interleukin 1 and tumor necrosis factor), and growth factors (TGFβ2, basic fibroblast growth factor, and platelet-derived growth factor) [12]. Patterns of VEGF expression observed in adults [13] have led to the hypothesis that cell-specific VEGF expression may be regulated as part of the process of cell differentiation, and our laboratory demonstrated that VEGF expression by skeletal muscle is

Correspondence to: Patricia A. D’Amore, Schepens Eye Research Institute/Massachusetts Eye and Ear, 20 Staniford St., Boston, MA, 02114; Phone: (617) 912-2559; FAX: (617) 912-0128; email: patricia.damore@schepens.harvard.edu
regulated in coordination with myogenic differentiation [14]. Motivated by these observations, we aimed the current study at determining whether VEGF expression is also regulated in concert with RPE differentiation.

Transcriptional regulation of VEGF occurs through the core promoter as well as through enhancers or repressors outside the core promoter domain. VEGF is unique in that its core promoter does not contain typical transcriptional initiation recognition sequences, such as a TATA box or a transcription factor II B recognition element [15]. Researchers have predicted that the VEGF promoter is controlled by an SP1 site located 50 base pairs upstream of the transcription start site [15,16]. Enhancement or repression of VEGF basal transcription can be controlled by the interaction of specific transcription factors with the VEGF promoter through, or independent of, the basal transcriptional machinery.

The key transcription factors involved in RPE specification include Pax6, Otx2, and microphthalmia-associated transcription factor (MITF). Pax6 is considered the master regulator of eye development, as the absence of this factor leads to complete failure of eye development, known as anophthalmia [17,18]. Pax6 expression ultimately becomes restricted to the primitive retina, whereas Otx2 and MITF are localized in the primitive RPE [19,20]. MITF is the key RPE-specifying transcription factor. Inactivation of MITF in mouse or quail impairs the development of the presumptive RPE; the RPE remains non-pigmented and hyperproliferates, becoming an additional neural retina [21]. Otx2 is thought to act in conjunction with MITF in a feedback loop to control RPE-specific gene expression. Otx2 overexpression in retinal cells leads to pigmentation; the presumptive RPE of mice deficient in Otx1/Otx2 is almost completely devoid of MITF expression, lacks pigmentation, and displays an RPE-to-retina transdifferentiation [20,22]. MITF belongs to the MITF-Tfe family of transcription factors, which are basic helix–loop–helix-leucine zipper transcription factors, including MITF, Tfe2, Tfe3, and Tfe4 [23]. Therefore, to test the hypothesis that VEGF regulation is coordinated with cell differentiation, we evaluated the MITF-Tfe family as candidate modulators of VEGF expression in the RPE.

METHODS

Cell culture, constructs, and transient transfections: ARPE-19, a human retinal pigment epithelium cell line, were purchased from ATCC (Mannassa, VA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/F12 1:1 supplemented with 10% fetal bovine serum (FBS) and 1% GlutaMAX, penicillin/streptomycin (GPS), and used through a maximum of 30 passages. ARPE-19 cells were induced to polarize by plating at high density (1.7 × 10^5 cells) on laminin-coated 0.4 μm-pore 12-well Costar Transwells (Thermo Fisher Scientific, Cambridge, MA), and maintained in DMEM/F12 supplemented with 1% FBS and 1% GPS. Media were changed twice a week for 4 weeks before use in experiments. Human embryonic kidney 293 (HEK 293) cells (ATCC) were maintained at subconfluence in DMEM (Gibco; Rockville, MD) supplemented with 10% FBS and 1% GPS. Both cell types were incubated at 37 °C in a 5% CO2 incubator and subcultured using trypsin.

For transfection with dominant negative MITF (kindly provided by David Fisher, Harvard Medical School, Boston, MA), which targets the MITF-Tfe transcription factor family, the ARPE-19 media were changed to 0.1% serum the day before transfection and maintained in low serum conditions throughout the experiment to minimize the effect of serum on VEGF expression. ARPE-19 cells were transfected at 65%–75% confluence using Lipofectamine LTX with PLUS reagent (Invitrogen, Carlsbad, CA) in 0.1% FBS DMEM/F12 for 24 h, and then fresh medium containing 0.1% FBS DMEM/F12 and GPS was added. At 48 h post-transfection, cells were washed in phosphate buffer solution (PBS; 137 mM NaCl; 2.7 mM KCl; 4.3 mM Na2HPO4; 1.47 mM KH2PO4, pH of 7.4; Sigma-Aldrich, Saint Louis, MO), and RNA was isolated to analyze gene expression with real-time PCR (qRT–PCR).

Immunofluorescence: Occludin was localized in polarized ARPE-19 cells. Cells were washed with PBS and fixed in ice-cold 4% paraformaldehyde for 10 min. After three washes in PBS, samples were blocked in 0.1% Triton/5% goat serum in PBS for 2 h at room temperature, and incubated with the occludin antibody (1:100; Invitrogen) overnight at 4 °C. After being washed with PBS, the samples were incubated with a mixture of fluorescein isothiocyanate (FITC)-conjugated goat antirabbit fluorescent secondary antibody (1:300; Jackson ImmunoResearch Laboratories; West Grove, PA) and 4',6-diamidino-2-phenylindole (DAPI; 1:100) for 1 h at room temperature. The Transwell membranes were cut around the periphery of the membrane with a razor blade, and then removed from the well with tweezers. The membranes were mounted on slides using aqueous mounting media consisting of 50% glycerol in PBS, and images were taken with an Axioskop (Axioskop MOT 2; Carl Zeiss Meditec, Inc., Dublin, CA).

Small interfering RNA–mediated gene silencing: Knockdown of MITF, Tfe2, and Tfe3 was achieved with 0.2 μM of ON-TARGETplus SMARTpools containing four pooled siRNA duplexes (Dharmacon; Lafayette, CO). A scrambled siRNA pool (0.2 μM) that lacks identity with known gene targets was used to control for non-sequence-specific effects. ARPE-19 cells were transfected as above, and three time points (24, 48, 72 h) were tested to determine the optimal post-transfection time to isolate mRNA. Of the three times, maximal gene downregulation was noted at 48 h and was therefore selected as the time point at which mRNA was isolated for analysis with qRT–PCR.

Luciferase reporter assays: ARPE-19 and HEK 293 cells at 75%–80% confluence were cotransfected using...
The cells were transfected overnight, and fresh medium was
added the following day. Lysates were collected 48 h post-
transfection, and luciferase expression was detected using the
dual-Luciferase Reporter Assay System (Promega) with a
transfectant control. Samples were normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) to confirm amplification specificity. Samples were run in
duplicate, and each experiment included two non-template
control wells. Samples were normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) according to the manufacturer’s instructions. VEGF promoter
activity, as indicated by the Fluc activity, was normalized to
Rluc. The ratio of Fluc to Rluc was then divided by the ratio of the promoterless luciferase to determine the fold change.

**Table 1. Real-time PCR primer sequences for human genes.**

| Primer name | Forward sequence | Reverse sequence |
|-------------|------------------|------------------|
| GAPDH       | CAAATTCATGCGACCAGTCA | GGAGTGGGCGTCGCTGGTA |
| MITF        | AGCCATCGAGTCGGGAAAT | ACTGCTGCTCTTACCCGG |
| Tfe3        | TACCTGAGGGCTCTTGGAAT | AGGTCAGAGAAGGCGTGTGA |
| Tfeb        | CGC ATCAAGGGTGGGAAT | CTCACGGGCGGAGAGT |
| TRP-1       | TCTCTGGGCTGTATCCTTCCA | GCACACATACCACTTCCCA |
| Tyrosinase  | CATTCTTCTCTCTTGCCAGA | CCGCTATCCAGAAGTGGGA |
| VEGF        | ATCGAGACCTTCGTGGGACA | CGCGCTCGGCTGTGACA |

Lipofectamine 2000 (Invitrogen) and FuGENE 6 (Roche
Diagnostics, Indianapolis, IN), respectively, with equal
amounts of VEGF firefly luciferase (Fluc)-reporter plasmid,
and Renilla control luciferase (Rluc; Promega, Madison, WI).
The cells were transfected overnight, and fresh medium was
added the following day. Lysates were collected 48 h post-
transfection, and luciferase expression was detected using the
Dual-Luciferase Reporter Assay System (Promega) with a
Turner Luminometer (Turner Designs, Sunnyvale, CA),
according to the manufacturer’s instructions. VEGF promoter
activity, as indicated by the Fluc activity, was normalized to
Rluc. The ratio of Fluc to Rluc was then divided by the ratio of the promoterless luciferase to determine the fold change.

**Real-time polymerase chain reaction analysis:** Total mRNA
was purified using RNA-Bee solution (Iso-Tex Diagnostic,
Inc., Friendswood, TX) under RNase-free conditions,
according to the manufacturer’s instructions. One microgram of RNA was reverse-transcribed using SuperScript III
(Invitrogen), and cDNA that was diluted 1:20 (50 ng of
equivalent RNA) was used in each amplification reaction.
Reactions were performed using the SYBR Green Master Mix
and the ABI Prism 9700 Sequence Detection System (Applied
Biosystems, Carlsbad, CA) according to the manufacturer’s
instructions. For primer sequences, see Table 1. The PCR
cycles consisted of an initial denaturation step at 95 °C for 10
min, followed by 40 cycles at 95 °C for 15 s and at 60 °C for
60 s. Each sample was also subjected to melting curve analysis
to confirm amplification specificity. Samples were run in
duplicate, and each experiment included two non-template
control wells. Samples were normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), and expressed as the
relative expression using the delta-delta Ct method. Results
are expressed as the mean±standard deviation.

**Enzyme-linked immunosorbent assay for determining
vascular endothelial growth factor levels:** Conditioned media
were collected from the apical and basolateral compartments of
ARPE-19 cells that were polarized over the course of 4
weeks. On the day before the conditioned media were
collected, the media were changed so that the levels of
secreted VEGF detected would reflect the amount of VEGF
secreted over the course of 24 h. The difference in volume of
the apical (500 μl) versus the basolateral (1.5 ml) compartment
was accounted for in the final calculation. VEGF levels were
determined with enzyme-linked immunosorbent assay
(ELISA; R&D Systems, Minneapolis, MN), according to the
manufacturer’s protocol.

**Statistical analysis:** Values are expressed as the mean
±standard deviation, unless otherwise indicated. Statistical
analysis was performed using an unpaired Student t test (**: p<0.01, *: p<0.05, ns: p>0.05).

**RESULTS**

**VEGF expression in the retinal pigment epithelium increased
during in vitro differentiation:** As the first step in elucidating
the molecular regulation of VEGF in the RPE, VEGF
expression was analyzed in ARPE-19 cells in an in vitro model
of cell maturation. ARPE-19 cells are an immortalized human
RPE cell line, a useful tool for studying RPE cells in vitro.
ARPE-19 cells recapitulate many characteristics of RPE in
vivo, including the distribution of VEGF isoform expression
[24], the formation of tight junctions [24,25], and increased
transepithelial resistance [25]. The in vitro model of
maturation consists of culturing cells in low serum on laminin-
coated Transwell membranes; ARPE-19 cells mature rapidly
over 4 weeks and continue to mature slowly thereafter [26].
Localization of occludin, a tight junction marker,
demonstrated a cuboidal monolayer, which is associated with
mature ARPE-19 cells (Figure 1). Compared to subconfluent
(70%) or confluent cells on plastic, VEGF in ARPE-19 cells
cultured for 6 weeks on Transwells was upregulated eightfold
(Figure 2). These ARPE-19 cells also displayed increased
expression of Pax6, MITF, and Otx2, the key RPE-specifying
transcription factors (Figure 2). Evaluation of VEGF protein
secretion during the 4 weeks of in vitro maturation revealed
that VEGF secretion correspondingly increased over time,
with approximately 189 pg/ml VEGF detected at week 4
compared to approximately 62 pg/ml at week 1. VEGF
secretion was polarized, occurring primarily (65%–72%)
toward the basolateral side of the RPE (Figure 3).

**Distal promoter regions are essential for VEGF expression in
the retinal pigment epithelium:** To begin to examine the
molecular basis of VEGF expression, constructs containing
various truncations of the VEGF promoter controlling
luciferase were used to determine the regions of the VEGF
promoter that are essential for VEGF expression in the RPE.
These constructs consisted of a 9 kb full-length VEGF promoter, as well as deletion mutants containing 5.2 kb, 2.1 kb, and 1.6 kb of upstream VEGF promoter (Figure 4). Analysis of these constructs in ARPE-19 cells revealed a twofold induction of promoter activity with the full-length 9 kb VEGF reporter construct over the 5.2 kb construct. Interestingly, similar induction of promoter activity was not observed in a control cell type (HEK 293), in which maximal promoter activity was obtained with the 2.1 kb construct (Figure 5). This observation suggests that RPE may express transcription factors or enhancers that bind specifically in the distal region of the VEGF promoter. Sequence analysis of the VEGF promoter revealed numerous binding sites for several transcription factors required for RPE specification; most notably, the putative binding sites for the MITF-Tfe transcription factor family were concentrated primarily in the -5 kb to -9 kb region (Figure 6).

MITF-Tfe family is involved in regulating VEGF in the retinal pigment epithelium: To determine if the transcription factors important for RPE specification might also be involved in regulating VEGF expression, the entire MITF-Tfe family was inhibited with dominant negative, or knocked down individually with siRNA. Overexpression of a dominant negative construct targeting the MITF-Tfe family led to a significant (50%) reduction in VEGF expression (Figure 7). The MITF-Tfe family of transcription factors are basic helix–loop–helix-leucine zipper transcription factors, including MITF, Tfeb, Tfe3, and Tfec [23]. These transcription factors may bind as homodimers or heterodimers to regulate gene transcription, making the pan MITF-Tfe dominant negative highly useful in determining the role of this transcription factor family in modulating gene expression. Notably, the downregulation of VEGF expression following pan MITF-Tfe blockade was seen only when transfections were performed in low serum (0.1%), indicating a role for serum factor in regulating VEGF expression. The extent of VEGF downregulation achieved with dominant negative pan MITF-Tfe closely paralleled that observed with the truncated 5.2 kb VEGF-luciferase reporter construct that lacks the region containing the binding sites for the MITF-Tfe family. Taken together, these findings support the notion that this family is involved in regulating VEGF expression, either directly or indirectly.

Figure 1. Occludin localization in polarized human retinal pigment epithelium (ARPE-19) cells. Occludin (green) and 4',6-diamidino-2-phenylindole (DAPI; blue) immunolocalization in ARPE-19 cells that were cultured for 4 weeks on Transwells to induce polarization reveals circumferential junctions and demonstrates a cuboidal monolayer. Scale bar is 50 μm.

Figure 2. Vascular endothelial growth factor (VEGF) and retinal pigment epithelium (RPE) transcription factor expression during RPE in vitro maturation. qRT–PCR analysis was performed on cDNA isolated from human retinal pigment epithelium (ARPE-19) cells that were maximally differentiated for 6 weeks and cells cultured on plastic that were 70% or 100% confluent. (A) VEGF and (B) RPE-transcription factors were upregulated in polarized ARPE-19 cells compared to non-polarized cells cultured on plastic. The experiment was performed in triplicate, and the results are expressed as the mean±standard deviation.
To determine which member(s) of the MITF-Tfe family may mediate VEGF regulation, pooled siRNA against MITF and Tfeb was used. MITF and Tfeb were successfully knocked down, individually and in combination, yet no effect of their knockdown on VEGF expression was observed (Figure 8). Tfe3 knockdown with siRNA led to a 20% reduction in VEGF mRNA; however, there was also a three- to fourfold increase in the known target genes of Tfe3 (tyrosinase-related protein 1 and tyrosinase; Figure 9). Although the knockdown of MITF, Tfeb, and Tfe3 was significant at 60%–80%, there is a possibility that even a low level of expression of these factors may be sufficient to influence VEGF expression in the RPE. Alternatively, there could be a redundancy among the family members so that inhibiting all members of the family would be necessary to affect VEGF expression. Nevertheless, these data provide compelling support for the concept that members of this family of transcription factors, particularly Tfe3, are involved in regulating VEGF expression in the RPE.

**DISCUSSION**

Analysis of ARPE-19 cells in vitro revealed that VEGF mRNA and protein secretion increased during culture for 4 to 6 weeks on Transwells during which time the cells matured rapidly. VEGF secretion by ARPE-19 may continue to increase during longer-term in vitro maturation (>1 month), but we also suspect that the secretion would eventually plateau. We found that VEGF protein secretion was also polarized, occurring primarily toward the basolateral side, which is consistent with the physiologic evidence that RPE-derived VEGF supports the underlying choriocapillaris. The preferential secretion of VEGF toward the basolateral side corroborated previous findings in primary human RPE cells [27]. Alternatively, another report suggested that the secretion may not be polarized, but rather that a higher rate of VEGF degradation and transcytosis at the apical surface of RPE cells accounts for the difference [28]. Nevertheless, the fact that the RPE uses such mechanisms further supports the physiologic importance of controlling the amount of VEGF secreted apically to retain an avascular outer retina. Given the role of VEGF as a potent angiogenic factor, it has been proposed that the outer retina is able to remain avascular by complementary apical secretion of the anti-angiogenic factor pigment epithelium-derived factor (PEDF) by the RPE. A recent study reported that PEDF secretion also increases in phenotypically polarized human embryonic stem cell-derived RPE [29].
Thus, a balance between angiogenic and antiangiogenic factor secretion is required to maintain eye homeostasis during development, and in the adult.

VEGF expression occurs early during eye development, at embryonic day 9.5 [24] when RPE specification is occurring. This observation combined with the increased VEGF expression during RPE maturation further supports the notion of coordinated regulation of VEGF expression and cell differentiation. VEGF functions to control tissue vascularization during development [5,30], and maintains the vasculature in the adult [31–33]. In light of these critical roles, it is not surprising that regulation of VEGF in the RPE might be synchronized with cell differentiation.

To directly test the hypothesis of regulation of VEGF coordinated with cell differentiation, the role of transcription factors involved in RPE specification in regulating VEGF expression was examined. Use of the pan MITF-Tfe dominant negative provided strong evidence that the MITF-Tfe family of transcription factors regulates VEGF expression in the RPE. This observation was supported by the fact that the distal region of the VEGF promoter, which contains putative binding sites for the MITF-Tfe family, was essential for expression by RPE, but not by HEK 293 cells. The fact that 50% was the maximum reduction of VEGF expression achieved using the pan MITF-Tfe dominant negative suggests that VEGF expression by the RPE is mediated by multiple mechanisms. The reduction of VEGF expression by the dominant negative MITF-Tfe was detected in 0.1% serum, and the remaining 50% of VEGF expression is likely due, at

Figure 5. Vascular endothelial growth factor (VEGF) promoter regions involved in regulating VEGF expression in RPE. (A) Human retinal pigment epithelium cell line (ARPE-19) or (B) HEK 293 cells were transfected with VEGF-luciferase constructs containing various truncations of the VEGF promoter. There was a twofold induction of promoter activity with the 9 kb construct over the 5.2 kb construct in (A) ARPE-19 cells. In (B) HEK 293 cells, maximum promoter activity was achieved with the 2.1 kb construct. The experiment was performed in triplicate. A representative experiment is shown with data expressed as the mean±standard deviation.

Figure 6. Schematic of putative binding sites for transcription factors in vascular endothelial growth factor (VEGF) promoter. The putative binding sites for the MITF-Tfe family are primarily concentrated in the -5 kb to -9 kb region of the VEGF promoter.

Figure 7. Overexpression of dnMITF leads to downregulation of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium (RPE). Human retinal pigment epithelium (ARPE-19) cells were transfected with a dominant negative against the MITF-Tfe transcription factor family (dnMITF) or an empty vector control (pBS). RNA was isolated 48 h post-transfection and analyzed with qRT–PCR. A 50% reduction in VEGF mRNA was observed in samples overexpressing the dnMITF; there was an 80% decrease in the expression of known targets for the MITF-Tfe family, tyrosinase (TYR), and tyrosinase-related protein-1 (TRP-1). The experiment was performed in triplicate. A representative experiment is shown with data expressed as the mean±standard deviation. *, p<0.05; ***, p<0.001.
least in part, to serum components, which have been shown to induce expression of VEGF family members [34].

Investigation of the relative contribution of individual MITF-Tfe family members revealed that of the family members tested, only knockdown of Tfe3 produced a reduction in VEGF expression. Interestingly, the reduction of VEGF expression occurred without a decrease in Tfe3 known targets. This observation is likely because alternative splicing of Tfe3 gives rise to two isoforms: Tfe3L and Tfe3S. Tfe3S, which lacks the N-terminal acidic activation domain present in Tfe3L, has a fourfold lower activation potential than Tfe3L, and has been reported to have a dominant negative effect against Tfe3L [35]. Therefore, knockdown of Tfe3S would eliminate its dominant negative effect and may well account for the increased expression of the downstream targets, tyrosinase-related protein 1 and tyrosinase. Given that depletion of the entire MITF-Tfe family was necessary to affect a 50% reduction in VEGF expression indicates functional redundancy among the members of the MITF-Tfe family.

The pattern and timing of VEGF expression in vivo are consistent with a role for the MITF-Tfe family in modulating VEGF expression by the RPE. MITF expression commences in the optic vesicle at E9.0, and by E9.5 MITF is localized primarily in the proximal optic vesicle, with less expression in the region of the optic vesicle adjacent to the surface ectoderm [21]. VEGF expression in the developing retina arises between E9.0 and E9.5, and at E9.5, VEGF is primarily detected in the proximal optic vesicle [24]. At E9.5, MITF and VEGF have similar patterns of expression. In addition, the Tfeb knockout mouse is embryonic lethal, with mice dying between E9.5 and E10.5 due to placental vascularization defects [36]. Interestingly, labyrinthine cells in the mutant Tfeb placenta failed to express VEGF, suggesting that Tfeb regulates VEGF in the placenta. Taken together with our findings, it appears that Tfe3, in conjunction with other MITF-Tfe members, may regulate VEGF expression in the RPE.

Figure 8. Knockdown of MITF and/or Tfeb does not affect vascular endothelial growth factor (VEGF) expression. Human retinal pigment epithelium (ARPE-19) cells were transfected with an siControl or a SMARTpool targeting MITF and/or Tfeb. Depletion of (A) MITF and/or (B) Tfeb did not reduce VEGF expression. The experiment was performed in triplicate. A representative experiment is shown with data expressed as the mean±standard deviation. *: p<0.05; ***: p<0.001; ns: p>0.05.

Figure 9. Tfe3 knockdown leads to a reduction in vascular endothelial growth factor (VEGF) expression. Human retinal pigment epithelium (ARPE-19) cells were transfected with an siControl or a SMARTpool targeting Tfe3. A: A 20% reduction in VEGF expression and (B) a three- to fourfold increase in Tfe3 downstream targets TRP-1 and tyrosinase were observed with Tfe3 depletion. The experiment was performed in triplicate. A representative experiment is shown with data expressed as the mean±standard deviation. *: p<0.05; **: p<0.01.
There is increasing evidence for a link between the development and progression of AMD and the status of the RPE. A recent report illustrated that oxidative stress can lead to RPE dedifferentiation and hypertrophy, which leads to decreased expression of several essential genes involved in RPE functions, including phagocytosis (MER tyrosine kinase), and the conversion of all-trans-retinal to 11-cis-retinal (RPE65) [37]. Interestingly, of the six RPE-characteristic markers tested in that study, only MITF increased in expression. The dysfunctional RPE may lead to photoreceptor cell death, while the elevated MITF could cause increased VEGF expression, promoting progression to the advanced form of AMD.

ACKNOWLEDGMENTS
The authors thank Dr. Eiichi Sekiyama for providing the image of occludin localization in polarized ARPE-19 cells, Tomoki Kurihara for performing the ELISA assay of the conditioned ARPE-19 media, and Mrs. Christine Bagley for her editorial assistance. This work was supported by RO1EY015435 (P.A.D.).

REFERENCES
1. Ciulla TA, Danis RP, Criswell M, Pratt LM. Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy. Expert Opin Investig Drugs 1999; 8:2173-82. [PMID: 11139846]
2. Muller YA, Christinger HW, Keyt BA, de Vos AM. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure 1997; 5:1325-38. [PMID: 9351807]
3. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29:10-4. [PMID: 12516033]
4. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246:1309-12. [PMID: 2479987]
5. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114:521-32. [PMID: 1592003]
6. Breier G, Clauss M, Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 1995; 204:228-39. [PMID: 8573716]
7. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declerq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435-9. [PMID: 8602241]
8. Ballermann BJ. Glomerular endothelial cell differentiation. Kidney Int 2005; 67:1668-71. [PMID: 15840009]
9. Esler S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998; 140:947-59. [PMID: 9472045]
10. Saint-Geniez M, Maldonado AE, D’Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 2006; 47:1315-42. [PMID: 16799060]
11. Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, Olsen BR. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005; 167:1451-9. [PMID: 16251428]
12. Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res 2007; 84:812-22. [PMID: 17331500]
13. Maharaj AS, Saint-Geniez M, Maldonado AE, D’Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006; 168:639-48. [PMID: 16436677]
14. Bryan BA, Walshe TE, Mitchell DC, Havumaki JS, Saint-Geniez M, Maharaj AS, Maldonado AE, D’Amore PA. Coordinated vascular endothelial growth factor expression and signaling during skeletal myogenic differentiation. Mol Biol Cell 2008; 19:994-1006. [PMID: 18094043]
15. Loureiro RM, D’Amore PA. Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev 2005; 16:77-89. [PMID: 15733833]
16. Shima DT, Kuroki M, Deutsch U, Ng Y-S, Adamis AP, D’Amore PA. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 1996; 271:3877-83. [PMID: 8632007]
17. Hogan BL, Horsburgh G, Cohen J, Hetherington CM, Fisher G, Lyon MF. Small eyes (Sey): a homoygous lethal mutation on chromosome 2 which affects the differentiation of both lens and nasal placodes in the mouse. J Embryol Exp Morphol 1986; 97:95-110. [PMID: 3794606]
18. Glaser T, Jepeal L, Edwards JG, Young SR, Favor J, Maas RL. PAX6 gene dosage effect in a family with congenital cataracts, aniridia, anophthalmia and central nervous system defects. Nat Genet 1994; 7:463-71. [PMID: 7951315]
19. Bäumer N, Marquardt T, Stoykova A, Spieler D, Treichel D, Ashery-Padan R, Gruss P. Retinal pigmented epithelium development: a view from the retina pigmented epithelium. Pigment Cell Res 2006; 19:380-94. [PMID: 16965267]
20. Nguyen M, Arnheiter H. Signaling and transcriptional regulation in early mammalian eye development: a link between FGF and MITF. Development 2000; 127:3581-91. [PMID: 9472045]
21. Martinez-Morales JR, Rodrigo I, Bovolenta P. Eye development: a view from the retina pigmented epithelium. Bioessays 2004; 26:766-77. [PMID: 15221858]
22. Steingrimsson E, Tessarollo L, Pathak B, Hou L, Arnheiter H, Copeland NG, Jenkins NA. Mitf and Tfe3, two members of the Mitf-Tfe family of HHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development.
development. Proc Natl Acad Sci USA 2002; 99:4477-82. [PMID: 11930005]

24. Ford KM, Saint-Geniez M, Walshe T, Zahr A, D’Amore PA. Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci 2011; 52:9478-87. [PMID: 22058334]

25. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 1996; 62:155-69. [PMID: 8698076]

26. Luo Y, Zhuo Y, Fukushima M, Rizzolo LJ. Effects of culture conditions on heterogeneity and the apical junctional complex of the ARPE-19 cell line. Invest Ophthalmol Vis Sci 2006; 47:3644-55. [PMID: 16877439]

27. Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer FR, van Hinsbergh VW, Schlingemann RO. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999; 155:421-8. [PMID: 10433935]

28. Peng S, Adelman RA, Rizzolo LJ. VEGF and Anti-VEGF drugs have minimal effects on the permeability or selectivity of RPE tight junctions. ARVO Annual Meeting; 2009 May 3–7; Fort Lauderdale (FL).

29. Zhu D, Deng X, Spee C, Sonoda S, Hsieh CL, Barron E, Pera M, Hinton DR. Polarized Secretion of PEDF from Human Embryonic Stem Cell-Derived RPE Promotes Retinal Progenitor Cell Survival. ARVO Annual Meeting; 2009 May 3–7; Fort Lauderdale (FL).

30. Carmeliet P, Ferriera V, Breier G, Pollefeyt S, Kieckens L, Gertenstein M, Fahrig M, Vandenhoock A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435-9. [PMID: 8602241]

31. Maharaj AS, D’Amore PA. Roles for VEGF in the adult. Microvasc Res 2007; 74:100-13. [PMID: 17532010]

32. Maynard SE, Min JY, Merchant J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellam IE, Epstein FH, Sukhatme VP, Karunamchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-58. [PMID: 12618519]

33. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O’Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290:H560-76. [PMID: 16172168]

34. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U, Alitalo K. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncproteins, and hypoxia. Oncogene 1997; 14:2475-83. [PMID: 9188862]

35. Artandi SE, Morrell K, Avitahl N, Wong KK, Calame K. TF[E3 contains two activation domains, one acidic and the other proline-rich, that synergistically activate transcription. Nucleic Acids Res 1995; 23:3865-71. [PMID: 7479029]

36. Steingrímsson E, Tessarollo L, Reid SW, Jenkins NA, Copeland NG. The bHLH-Zip transcription factor Tfeb is essential for placental vascularization. Development 1998; 125:4607-16. [PMID: 9806910]

37. Zhao C, Yasumura D, Li X, Matthes M, Lloyd M, Nielsen G, Ahern K, Snyder M, Bok D, Dunatief JL, LaVail MM, Vollrath D. mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J Clin Invest 2011; 121:369-83. [PMID: 21135502]